Hegseth's Testosterone Plan Leaves Soldier Risks Unanswered

The FDA's expert panel on TRT met in December 2025 to discuss monitoring protocols. The Department of Health and Human Services has since asked for revised treatment guidelines. The request cited recent studies showing cardiovascular and prostate cancer risks are lower than previously reported. Still, those studies do not address the specific population of young active-duty men starting TRT in their 30s.

Fertility effects are a particular concern for this group. TRT can suppress sperm production. The Pentagon has not addressed how it will handle informed consent or long-term monitoring for troops who may want children later. High testosterone levels can also cause sleep issues, excess body hair, liver disease, and mood disorders. The balance between the benefits of supplementation and the unknowns is unresolved.

The FDA panel's December meeting and HHS's request for updated guidelines set the stage for potential changes to how TRT is prescribed and monitored. No timeline for new federal guidelines has been announced.